What is SXTP's current stock price?

SXTP (60 Degrees Pharmaceuticals, Inc.) is currently trading at $1.48 with a market cap of $1.2M.

What sector is 60 Degrees Pharmaceuticals, Inc. in?

60 Degrees Pharmaceuticals, Inc. (SXTP) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

SXTP 60 Degrees Pharmaceuticals, Inc.

Healthcare

$1.48-0.67%ClosedMarket Cap: $1.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.53

P/S

1.19

EV/EBITDA

0.27

DCF Value

$-28.19

FCF Yield

-688.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

20.9%

Operating Margin

-791.1%

Net Margin

-755.2%

ROE

-200.2%

ROA

-112.1%

ROIC

-162.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$162.1K	$-2.1M	$—
Q4 null	$303.4K	$-1.4M	$—
FY null	$1.0M	$-7.4M	$—
Q3 null	$437.6K	$-2.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell

Ascendiant CapitalBuy

2026-05-22

HC Wainwright & Co.Neutral

2026-05-20

Ascendiant CapitalBuy

2026-04-09

HC Wainwright & Co.Buy

2026-01-27

Ascendiant CapitalBuy

2025-11-28

Trading Activity

Insider Trades

View All

Francois Ericdirector:

SellTue May 19

DOW GEOFFREY Sdirector, officer: President and CEO

BuyTue Dec 16

DOW GEOFFREY Sdirector, officer: President and CEO

BuyFri Dec 12

DOW GEOFFREY Sdirector, officer: President and CEO

BuyFri Dec 12

DOW GEOFFREY Sdirector, officer: President and CEO

SellMon Sep 15

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.70

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.

Peers

GRI